Clementia Pharmaceuticals Inc.

Donna Roy Grogan

Clarissa Desjardins

Jeffrey Neal Packman

Mark Harnett

Isabelle Lemire

Michael Harvey

The invention features dosing regimens and pharmaceutical formulations for oral administration of palovarotene. The dosing regimens can reduce heterotopic ossification, reduce the number of flare-ups, and/or reduce the severity of flare-ups in subjects suffering from fibrodysplasia ossificans progressiva.

Methods for treating heterotopic ossification

The invention features methods for inhibiting the formation, reducing the size, and slowing the growth of an osteochondroma in a subject with multiple osteochondroma (MO) by administering to the subject palovarotene (also known as R667), or a pharmaceutically acceptable salt thereof. The methods described herein can also ameliorate complications associated with osteochondroma formation and growth in a subject with MO.

Growing community of inventors

Boston, MA, United States of America

Donna Roy Grogan